Connect Biopharma Holdings Limited
CNTB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.01 | 0.01 | -0.02 |
| FCF Yield | -31.97% | -74.21% | -216.73% | -34.56% |
| EV / EBITDA | 0.09 | 0.69 | 0.27 | -0.01 |
| Quality | ||||
| ROIC | -24.46% | -60.76% | -73.13% | -36.30% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.51 | 0.81 | 0.85 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 49.48% | 53.43% | -11.31% | -232.83% |
| Safety | ||||
| Net Debt / EBITDA | 3.58 | 1.80 | 0.68 | 1.33 |
| Interest Coverage | 0.00 | 0.00 | -5,594.41 | -14,350.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.16 | 0.00 |
| Cash Conversion Cycle | 14.74 | -2,829.86 | -6,501.85 | 0.00 |